Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–37 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Hypomethylating agents Clear all
Active, not recruiting Phase 3 Interventional

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

NCT02665065
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
Interventions
Iomab-B, Conventional Care, HCT
Drug · Procedure
Lead sponsor
Actinium Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 28, 2026, 9:12 PM EDT
Completed Phase 3 Interventional

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)

NCT01147939
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Elacytarabine, Investigator's Choice
Drug
Lead sponsor
Clavis Pharma
Industry
Eligibility
18 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Sep 28, 2026, 9:12 PM EDT
Recruiting Phase 2 Interventional

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

NCT05442216
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Tagraxofusp, Azacitidine, Venetoclax
Drug
Lead sponsor
Joshua Zeidner
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
7
States / cities
Miami, Florida • Orlando, Florida • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 28, 2026, 9:12 PM EDT
Recruiting Phase 2 Interventional

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

NCT05983276
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Decitabine, Carboplatin, Paclitaxel, Selinexor
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 28, 2026, 9:12 PM EDT
Terminated Phase 2 Interventional Results available

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

NCT03946670
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
MBG453, Placebo, Hypomethylating agents
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Duarte, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 28, 2026, 9:12 PM EDT
Withdrawn No phase listed Observational

DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US

NCT02863458
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
66 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Sep 28, 2026, 9:12 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

NCT03761914
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Interventions
galinpepimut-S, pembrolizumab, Montanide, GM-CSF
Biological · Other
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
12
States / cities
Santa Rosa, California • Whittier, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 28, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome

NCT02117219
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
MEDI4736 Evaluate MEDI4736 in MDS, VIDAZA, tremelimumab
Biological · Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Sep 28, 2026, 9:12 PM EDT
Not yet recruiting Phase 2 Interventional

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

NCT07060001
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)
Interventions
5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days, Azacitidine (AZA), Cytarabine (Ara-C), Anthracycline
Diagnostic Test · Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 28, 2026, 9:12 PM EDT
Active, not recruiting Phase 2 Interventional

Cladribine Venetoclax in Monocytic AML

NCT06232655
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cladribine, Venetoclax, Azacitidine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 28, 2026, 9:12 PM EDT
Active, not recruiting Phase 2 Interventional

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

NCT05201066
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Interventions
decitabine, spartalizumab, sabatolimab, azacitidine, venetoclax, INQOVI (oral decitabine)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Portland, Oregon • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 28, 2026, 9:12 PM EDT
Withdrawn Phase 2 Interventional

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

NCT01520805
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
CPI-613
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cranbury, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 28, 2026, 9:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

NCT02929498
View directory record Official record
Conditions
Myelodysplastic Syndrome, Myelodysplastic Syndromes
Interventions
GSK2879552, Azacitidine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Augusta, Georgia • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Sep 28, 2026, 9:12 PM EDT